To study the therapeutic effect of radioimmunotherapy targeting MUC1, a large multicenter phase III clinical trial was carried out in a total of 447 patients with epithelial ovarian cancer who had attained a complete clinical remission after cytoreductive surgery and platinum-based chemotherapy with yttrium-90-labeled murine HMFG1 (90Y-muHMFG1). The gene discussed is MUC1; the disease is ovarian carcinoma.